查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585838

支气管炎治疗药物市场：按药物类型、应用分类 - 全球预测 2025-2030

Bronchitis Drugs Market by Drug Type (Anti-inflammatory Drugs, Antibiotics, Bronchodilators), Application (Acute Bronchitis, Chronic Bronchitis) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年支气管炎治疗药物市值为15.4亿美元，预计到2024年将达到16.8亿美元，复合年增长率为9.74%，预计到2030年将达到29.6亿美元。

支气管炎药物市场的特点是其范围包括专门用于缓解症状和治疗急慢性支气管炎的非处方药和处方药。其中包括抗生素、发炎、支气管扩张剂、止咳药和其他形式的药物，这些药物对于减少发炎和控制患者支气管症状非常重要。这些药物的使用在解决呼吸问题（从即时缓解症状到长期管理）方面发挥着重要作用，凸显了它们在医疗保健方面的需求。最终用途主要是在医院、诊所和家庭护理机构中常规使用这些药物。呼吸系统疾病发病率的增加、污染水平的上升导致支气管炎患者的增加以及更容易患呼吸系统疾病的老年人口的增加推动了市场的成长。最近的趋势凸显了对高效能、速效药物的需求，以及对植物来源或草药治疗日益增长的兴趣，提供了新的潜在机会。公司可以透过投资个人化医疗等创新解决方案的研发、利用生物技术和基因组学的进步以及探索植物来源化合物来增加资本。然而，抗生素抗药性危机、潜在副作用以及新兴市场缺乏意识等挑战可能会阻碍成长。监管障碍和严格的核准流程是主要限制因素，需要可靠的资料和测试。临床试验以及与医疗机构合作开发具有成本效益的药物可以解决这些障碍。此外，远端医疗和人工智慧健康监测等数位健康技术可能为患者参与和药物管理提供新途径，反映了市场的动态本质。总体而言，创新的机会在于开发环保产品、加强药物输送系统以及扩大服务欠缺地区获得支气管炎治疗的机会，同时支持永续的业务增长，跟上不断变化的监管环境和以患者为中心的护理非常重要。

主要市场统计
基准年[2023] 15.4亿美元
预测年份 [2024] 16.8亿美元
预测年份 [2030] 29.6亿美元
复合年增长率（%） 9.74%

市场动态：揭示快速发展的支气管炎药物市场的关键市场洞察

供应和需求的动态交互作用正在改变支气管炎药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 老年人口增加导致呼吸系统疾病增加
    • 吸烟等不健康习惯增加
    • 工业扩张导致慢性支气管炎发生率增加
  • 市场限制因素
    • 生产支气管炎治疗药物投资成本高
  • 市场机会
    • 政府和私人组织增加对支气管炎治疗方法研发的投资
    • 製造商之间策略联盟的增加
  • 市场挑战
    • 核准流程规定严格、程序复杂

波特五力：驾驭支气管炎药物市场的策略工具

波特的五力架构是了解支气管炎治疗药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对支气管炎治疗药物市场的影响

外部宏观环境因素在塑造支气管炎治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解支气管炎治疗药物市场的竞争状况

支气管炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵支气管炎治疗市场供应商的绩效评估

FPNV 定位矩阵是评估支气管炎治疗药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘支气管炎治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对支气管炎治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老化社会呼吸系统疾病发生率上升
      • 吸烟等不健康习惯在人群中不断增加
      • 工业扩张增加慢性支气管炎发生率
    • 抑制因素
      • 生产支气管炎治疗药物的投资成本很高。
    • 机会
      • 政府和私人组织增加对支气管炎治疗方法研发的投资
      • 扩大製造商之间的策略合作
    • 任务
      • 核准流程规定严格、程序复杂
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 依药物类型分類的支气管炎治疗药物市场

  • 发炎药
  • 抗生素
  • 支气管扩张剂
  • 黏液溶解药

第七章支气管炎治疗药物市场：依应用分类

  • 急性支气管炎
  • 慢性支气管炎

第八章 北美和南美支气管炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区支气管炎治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲支气管炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alembic Pharmaceuticals Ltd.
  • Apotex Inc.
  • Boehringer Ingelheim International GmbH
  • DLC Laboratories, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Jamp Pharma Corporation
  • Marlex Pharmaceuticals, Inc.
  • Novartis International AG
  • Sandoz AG
  • Sanofi SA
  • Sun Pharmaceutical Industries, Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05239

The Bronchitis Drugs Market was valued at USD 1.54 billion in 2023, expected to reach USD 1.68 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 2.96 billion by 2030.

The bronchitis drugs market is characterized by its scope, which encompasses over-the-counter and prescription medications tailored to alleviate symptoms and treat acute and chronic bronchitis. The scope extends to various forms of drugs such as antibiotics, anti-inflammatory drugs, bronchodilators, and cough suppressants, crucial for reducing inflammation and managing bronchial symptoms in patients. The application of these medications plays a vital role in addressing respiratory issues, from immediate symptom relief to long-term management, highlighting their necessity in healthcare. End-use is primarily within hospitals, clinics, and home care settings where these medications are routinely prescribed. Market growth is propelled by increasing incidences of respiratory diseases, rising pollution levels contributing to higher bronchitis cases, and a growing geriatric population prone to respiratory conditions. Recent trends emphasize the demand for efficient and rapid-acting drugs alongside a burgeoning interest in plant-based or herbal treatments, offering new potential opportunities. Companies could capitalize by investing in R&D for innovative solutions like personalized medicine, leveraging advances in biotechnology and genomics, or exploring plant-derived compounds. However, challenges such as the antibiotic resistance crisis, potential side effects, and the lack of awareness in emerging markets could impede growth. Regulatory hurdles and stringent approval processes pose significant limitations, requiring robust data and trials. Collaborations with healthcare institutions for clinical studies and the development of cost-effective medications can address such barriers. Additionally, digital health technologies including telemedicine and AI-driven health monitoring could offer novel avenues for patient engagement and medication management, reflecting the market's dynamic nature. Overall, innovation opportunities lie in developing eco-friendly products, enhancing drug delivery systems, and expanding access to bronchitis treatments in underserved regions, while staying abreast of evolving regulatory landscapes and patient-centric care models for sustainable business growth.

KEY MARKET STATISTICS
Base Year [2023] USD 1.54 billion
Estimated Year [2024] USD 1.68 billion
Forecast Year [2030] USD 2.96 billion
CAGR (%) 9.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchitis Drugs Market

The Bronchitis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of respiratory problems in the growing elderly population
    • Growing unhealthy habits such as smoking among the population
    • Expansion of industries increases the incidence of chronic bronchitis
  • Market Restraints
    • High cost of investment in production of bronchitis drugs
  • Market Opportunities
    • Increasing investments from government and private organizations for research and development of bronchitis drugs
    • Growing strategic collaborations among manufacturers
  • Market Challenges
    • Strict regulations and cumbersome procedure in the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Bronchitis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchitis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchitis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchitis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchitis Drugs Market

A detailed market share analysis in the Bronchitis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchitis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchitis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchitis Drugs Market

A strategic analysis of the Bronchitis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchitis Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Ltd., Apotex Inc., Boehringer Ingelheim International GmbH, DLC Laboratories, Inc., Dr. Reddy's Laboratories Ltd., Fresenius Kabi, GlaxoSmithKline Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Jamp Pharma Corporation, Marlex Pharmaceuticals, Inc., Novartis International AG, Sandoz AG, Sanofi S.A., Sun Pharmaceutical Industries, Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anti-inflammatory Drugs, Antibiotics, Bronchodilators, and Mucolytics.
  • Based on Application, market is studied across Acute Bronchitis and Chronic Bronchitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of respiratory problems in the growing elderly population
      • 5.1.1.2. Growing unhealthy habits such as smoking among the population
      • 5.1.1.3. Expansion of industries increases the incidence of chronic bronchitis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of investment in production of bronchitis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments from government and private organizations for research and development of bronchitis drugs
      • 5.1.3.2. Growing strategic collaborations among manufacturers
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulations and cumbersome procedure in the approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchitis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-inflammatory Drugs
  • 6.3. Antibiotics
  • 6.4. Bronchodilators
  • 6.5. Mucolytics

7. Bronchitis Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Acute Bronchitis
  • 7.3. Chronic Bronchitis

8. Americas Bronchitis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Bronchitis Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Bronchitis Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alembic Pharmaceuticals Ltd.
  • 2. Apotex Inc.
  • 3. Boehringer Ingelheim International GmbH
  • 4. DLC Laboratories, Inc.
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Fresenius Kabi
  • 7. GlaxoSmithKline Pharmaceuticals Ltd.
  • 8. Glenmark Pharmaceuticals Ltd.
  • 9. Jamp Pharma Corporation
  • 10. Marlex Pharmaceuticals, Inc.
  • 11. Novartis International AG
  • 12. Sandoz AG
  • 13. Sanofi S.A.
  • 14. Sun Pharmaceutical Industries, Ltd.
  • 15. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BRONCHITIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHITIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BRONCHITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BRONCHITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHITIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHITIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ACUTE BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM BRONCHITIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. BRONCHITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. BRONCHITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023